Table 1.
Characteristics of the Study Population for the rs8050136 of the FTO gene*
| CC (n = 66) |
CA/AA (n = 99) |
P value† | |
|---|---|---|---|
| Age (years) | 69.0 ± 3.7 | 70.0 ± 4.9 | 0.17 |
| Female sex (%) | 45 (68.2) | 61 (62.2) | 0.87 |
| College graduate (%) | 39 (59.1) | 63 (63.6) | 0.63 |
| Married (%) | 32 (48.5) | 54 (54.5) | 0.44 |
| Race/ethnicity (%) | 0.40 | ||
| Non-Hispanic white | 48 (72.7) | 76 (76.8) | |
| Hispanic white | 12 (18.2) | 10 (10.1) | |
| African-American | 5 (7.6) | 9 (9.1) | |
| Other/multiple | 1 (1.5) | 4 (4.0) | |
| Frailty measures | |||
| PPT score | 28.3 ± 2.7 | 28.0 ± 3.3 | 0.78 |
| VO2peak (ml/kg/min) | 16.6 ± 3.6 | 17.5 ± 3.6 | 0.18 |
| FSQ score | 30.5 ± 3.3 | 30.2 ± 3.1 | 0.54 |
| Knee extension strength (Nm) | 69.9 ± 24.9 | 70.9 ± 25.0 | 0.95 |
| Knee flexion strength (Nm) | 43.4 ± 15.3 | 44.5 ± 17.8 | 0.85 |
| History of cardiovascular disease, n (%) | 21 (31.8) | 33 (33.3) | 0.84 |
| Previous cigarette use, n (%) | 17 (25.8) | 22 (22.2) | 0.60 |
| Medication use | |||
| Antihypertensive, n (%) | 34 (53.1) | 50 (51.0) | 0.80 |
| Antidyslipidemic, n (%) | 16 (24.2) | 25 (25.3) | 0.52 |
| Antacid/proton-pump inhibitor (%) | 11 (16.7) | 18 (18.2) | 0.80 |
| Antiallergic (%) | 13 (19.7) | 14 (14.1) | 0.35 |
| Analgesic/nonsteroidal (%) | 18 (25.8) | 36 (36.4) | 0.22 |
| Psychotropic (%) | 7 (10.6) | 16 (16.2) | 0.31 |
| Multivitamin/supplement (%) | 17 (25.8) | 33 (33.3) | 0.30 |
*
Values are given as mean ± SD or number (percentage) of participants unless otherwise specified.
†
P-values as calculated by independent t tests for continuous variables and Chi square test for categorical variables.
Abbreviations: PPT = Modified Physical Performance Test range from 0 to 36, with higher scores indicating better physical function. Peak oxygen consumption (VO2peak) was assessed during graded treadmill walking. Scores on the Functional Status Questionnaire (FSQ) range from 0 to 36, with higher scores indicating better functional status. Nm = Newton meter.